Abelson murine leukaemia virus (AbMuLV) is an acutely transforming retrovirus which induces lymphoid neoplasms in mice with latent periods of 3–5 weeks1. The oncogenicity of AbMuLV is attributed to expression of a viral transforming gene (v-abl) which encodes a protein with tyrosine-specific kinase activity2. Two recent findings, however, suggest that oncogenesis by AbMuLV may not be a single-step consequence of v-abl expression. First, Whitlock and Witte3 observed that AbMuLV infection of bone marrow cells in vitro stimulated proliferation of immature blast cells which did not exhibit the in vitro growth properties or tumorigenicity characteristic of cells from AbMuLV-induced neoplasms. These AbMuLV-infected cell populations evolved to fully neoplastic cells only after several weeks in culture, suggesting that secondary events were required for expression of the neoplastic phenotype3. Second, Grunwald et atl.4 reported the loss of the AbMuLV genome after prolonged in vivo passage of some AbMuLV-induced neoplasms, suggesting that expression of v-abl may be necessary for initiation, but not maintenance, of transformation. We report here that AbMuLV-induced neoplasms contain cellular transforming genes detectable by transfection which are distinct from AbMuLV sequences. Taken together, these results suggest that v-abl expression may induce early events in the neoplastic process and that secondary activation of a distinct cellular transforming gene may be involved in progression to neoplasia.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Abelson, H. T. & Rabstein, L. S. Cancer Res. 30, 2213–2222 (1970).
Witte, O. N., Goff, S., Rosenberg, N. & Baltimore, D. Proc. natn. Acad. Sci. U.S.A. 77, 4993–4997 (1980).
Whitlock, C. A. & Witte, O. N. J. Virol. 40, 577–584 (1981).
Grunwald, D. J. et al. J. Virol. 43, 92–103 (1982).
Dessner, D. S. & Loken, M. R. Eur. J. Immun. 11, 282–285 (1981).
Kincade, P. W., Lee, G., Watanabe, T., Sun, L. & Scheid, M. J. Immun. 127, 2262–2268 (1981).
Lane, M.-A., Sainten, A. & Cooper, G. M. Cell 28, 873–880 (1982).
Srinivasan, A., Reddy, E. P. & Aaronson, S. A. Proc. natn. Acad. Sci. U.S.A. 78, 2077–2081 (1981).
Goff, S. P., Gilboa, E., Witte, O. N. & Baltimore, D. Cell 22, 777–785 (1980).
Srinivasan, A. et al. Proc. natn. Acad. Sci. U.S.A. 79, 5508–5512 (1982).
Cooper, G. M. & Neiman, P. E. Nature 287, 656–659 (1980).
Lane, M. A., Sainten, A. & Cooper, G. M. Proc. natn. Acad. Sci. U.S.A. 78, 5185–5189 (1981).
Hayward, W. S., Neel, B. G. & Astrin, S. M. Nature 290, 475–480 (1981).
Cooper, G. M. & Neiman, P. E. Nature 292, 857–858 (1981).
Degrand, D. & Rosenberg, N. Cetus-UCLA Symp. Tumor Viruses and Differentiation (in the press).
Cook, W. D. Proc. natn. Acad. Sci. U.S.A. 79, 2917–2921 (1982).
Raschke, W. C., Baird, S., Ralph, P. & Nakoinz, I. Cell 15, 261–267 (1978).
Southern, E. M. J. molec. Biol. 98, 503–517 (1975).
About this article
Cite this article
Lane, M., Neary, D. & Cooper, G. Activation of a cellular transforming gene in tumours induced by Abelson murine leukaemia virus. Nature 300, 659–661 (1982). https://doi.org/10.1038/300659a0
Cancer Investigation (1988)
International Journal of Cardiology (1988)
Clinica Chimica Acta (1986)
International Journal of Cancer (1985)